Sinopharm has yet to comment which vaccines were used in the emergency program and Jingzhen was unclear about which vaccine he was addressing.
Almost a million people in China have taken an experimental coronavirus vaccine through the country's emergency use program as of Wednesday, according to vaccine developer China National Pharmaceutical Group (Sinopharm).
The phase 2 trial did not look at how well the vaccine protected volunteers from infection. The terms of references for two major bodies dealing with vaccine introduction - the National Technical Advisory Group on Immunisation (NTAGI) and the Central Drug Standards and Control Organisation (CDSCO) - will be set and their roles clearly defined for authorisation and emergency authorisation. The data from an emergency program is inefficient and unable to determine a vaccine's effectiveness.
"In terms of emergency use, the vaccines were applied to almost a million people and there has not been a single case of a serious adverse event". He told the British Broadcasting Corporation (BBC) on Thursday that he was "delighted" that early results show a strong immune response "even in those over 70 years of age".
The new results show that two doses of the vaccine will be needed for each person.
ChAdOx1 nCov-2019 vaccine is now undergoing its Phase 3 trial with 40,051 participants now enrolled. 40,000 participants have had blood samples taken upon being administered the second dose, said Jingzhen. These developments assume significance against the backdrop of Pfizer seeking emergency use authorisation of its COVID-19 vaccine from the United States regulators.
Sadhguru Jaggi Vasudev on Saturday appealed to give top priority to provide Covid vaccine to high-risk groups including doctors, police personnel and frontline workers managing the outbreak. The phase 3 trial was briefly put on pause before it restarted late last month. Pfizer and BioNTech then followed by Wednesday and said their candidate was in fact 95 percent effective against COVID-19 as well.
"Inducing robust immune responses in older adults has been a long-standing challenge in human vaccine research", Dr Angela Minassian, Investigator at the University of Oxford and Honorary Consultant in Infectious Diseases said in a statement. Demand is clearly high, and several wealthy nations already have their pre-orders in place.